Baishen Zhang
Overview
Explore the profile of Baishen Zhang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
91
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang B, Bao H, Li Z, Chen J, Yu H, Li M, et al.
Lung Cancer
. 2024 Dec;
199:108021.
PMID: 39705825
Introduction: Small cell lung cancer (SCLC) is a highly malignant tumor with an extremely poor prognosis. In the currentera of immunotherapy, the role of immune checkpoint inhibitors (ICIs) in the...
2.
Zhang B, Chen J, Yu H, Li M, Chen L
Transl Lung Cancer Res
. 2024 Nov;
13(10):2479-2490.
PMID: 39507022
Background: Brain metastases (BM) are highly prevalent and associated with a poor prognosis in patients with small cell lung cancer (SCLC). However, the evidence regarding the efficacy of immune checkpoint...
3.
Zhang B, Liu Y, Chen Z, Chen J, Yu H, Li M, et al.
Int J Cancer
. 2024 Apr;
155(4):710-718.
PMID: 38608177
Thymic carcinoma (TC) is a rare malignant tumor with a poor prognosis, and there is currently limited data on the use of immunotherapy in patients with unresectable TC. In this...
4.
Zhang B, Chen J, Yu H, Li M, Cai M, Chen L
J Inflamm Res
. 2024 Mar;
17:1777-1788.
PMID: 38523686
Background: Currently, there is a lack of well-established markers to predict the efficacy of chemoimmunotherapy in small-cell lung cancer (SCLC). Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), advanced lung cancer inflammation...
5.
Li M, Chen J, Yu H, Zhang B, Hou X, Jiang H, et al.
Oncoimmunology
. 2024 Jan;
13(1):2290790.
PMID: 38169917
Background: Immunotherapy has shown intracranial efficacy in non-small cell lung cancer (NSCLC) patients with brain metastases. However, predictive biomarkers for intracranial response to immunotherapy are lacking. This post-hoc analysis aimed...
6.
Wang N, Zheng L, Li M, Hou X, Zhang B, Chen J, et al.
Lung Cancer
. 2023 Mar;
178:183-190.
PMID: 36868179
Introduction: Pembrolizumab is recommended with a fixed dose of 200 mg 3-weekly. We performed this study to explore the clinical efficacy and safety of pharmacokinetic (PK)-guided pembrolizumab administration in advanced...
7.
Hou X, Li M, Wu G, Feng W, Su J, Jiang H, et al.
JAMA Netw Open
. 2023 Feb;
6(2):e2255050.
PMID: 36753281
Importance: Use of tyrosine kinase inhibitors (TKIs) is the standard therapy for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) with brain metastases. Several studies have shown that...
8.
Li M, Chen J, Zhang B, Yu J, Wang N, Li D, et al.
BMC Med
. 2023 Jan;
21(1):15.
PMID: 36617568
No abstract available.
9.
Li M, Chen J, Zhang B, Yu J, Wang N, Li D, et al.
BMC Med
. 2022 Nov;
20(1):398.
PMID: 36372873
Background: Due to the blood-brain barrier, plasma is not an ideal source to evaluate the genetic characteristics of central nervous system tumors. Thus, cerebrospinal fluid (CSF) is becoming an alternative...
10.
Li M, Hou X, Sai K, Wu L, Chen J, Zhang B, et al.
Oncoimmunology
. 2022 Apr;
11(1):2059874.
PMID: 35402080
Lung cancer is one of the most common causes of brain metastases and is always associated with poor prognosis. We investigated the immunophenotypes of primary lung tumors and paired brain...